Souhaitez-vous accéder aux communiqués récents ?

Increased revenue by 128% year over year (YoY) to $1.8 million Appointed Beyond Air Board member Bob Goodman as Interim Chief Commercial Officer Raised $12.0 million in debt financing; proforma...

Webcast Recording and Symposium Slides Now Available LAWRENCEVILLE, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its...

Austin, TX, USA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Construction Anchors Market Size, Trends and Insights By Product (Hangers,...

NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of ZoomInfo Technologies, Inc. (NASDAQ: GTM)...

Ottawa, Nov. 10, 2025 (GLOBE NEWSWIRE) -- The global mice model market size is expected to be worth over USD 19.36 billion by 2034, increasing from USD 12.12 billion in 2026, growing at a strong...

Dublin, Nov. 10, 2025 (GLOBE NEWSWIRE) -- The "India Chemotherapy at Home Service Market, By Region, By Competition, Opportunities & Forecast, 2020-2030F" has been added to ...

OCALA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today detailed a recent abstract containing data from the completed Phase 2 advanced...

Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)

Australian needle-free vaccine patch company Vaxxas appoints global pharmaceutical executive to Board as it accelerates product to market.

Phase 2a data support oral C5aR inhibitor INF904 as a potentially transformational and best-in-class immunomodulatory agent, indicating strong potential for efficacy and no safety signals of concernIn...